Three Regulatory Precedents for Using NAMs for Decisions on Inhaled Substances: How to Promote Alternative Methods Without Eroding Public Health Protections?
Toxicological Sciences · 13.11.2026
DOI: 10.1093/toxsci/kfag152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 13.11.2026. Verfasst von Ivan Rusyn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843 USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Inhalation risk assessments have long relied on rodent bioassays to derive points of departure (PODs) for human health decisions, yet species differences in respiratory anatomy, breathing, and deposition introduce substantial uncertainty when extrapolating to humans (Stucki et al., 2024).Animal data are particularly challenging for portal-of-entry irritants, for which local effects at the contact site can preclude establishing a no observed adverse effect level (NOAEL) from traditional rodent studies.New Approach Methodologies (NAMs), including human 3D airway tissue models, computational fluid dynamics (CFD)/aerosol deposition modeling, and in vitro-to-in vivo extrapolation (IVIVE), offer a mechanistically grounded, human-relevant alternative that can reduce interspecies uncertainty and expand dose-response and chemical-class coverage.Greater reliance on NAM data also aligns with recent worldwide efforts to reduce or eliminate animal testing for chemical safety evaluation (European Commission, 2026).NAMs are developing rapidly, and many Organisation for Economic Cooperation and Development (OECD) test guideline studies already do not rely on animals; however, non-OECD guideline NAM-derived data have only recently been incorporated into formal risk decisions.The three case studies below illustrate this evolving regulatory landscape, including precedents for how such data are used to refine, or replace animalbased PODs.Precedent 1: Chlorothalonil -US EPA Office of Pesticide Programs (OPP).This case is widely acknowledged as the first use of a human in vitro NAM in an EPA inhalation risk assessment.Chlorothalonil is a fungicide for which no NOAEL could be established in a 14-day rat inhalation study because concentration-dependent nasal and laryngeal epithelial necrosis, inflammation, and metaplasia occurred even at the lowest tested doses.Because chronic studies were infeasible given portal-of-entry cytotoxicity, the sponsor proposed in 2014 that the traditional rodent study be replaced with the MucilAir 3D human bronchial tissue model.A comprehensive dataset was
Autor:innen und Institutionen
- Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843 USA.
Zitieren
APA
Rusyn, I., & Chiu, W. A. (2026). Three Regulatory Precedents for Using NAMs for Decisions on Inhaled Substances: How to Promote Alternative Methods Without Eroding Public Health Protections?. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfag152
Vancouver
Rusyn I, Chiu WA. Three Regulatory Precedents for Using NAMs for Decisions on Inhaled Substances: How to Promote Alternative Methods Without Eroding Public Health Protections?. Toxicological Sciences. 2026. doi:10.1093/toxsci/kfag152
BibTeX
@article{Rusyn2026,
author = {Rusyn, Ivan and Chiu, Weihsueh A},
title = {Three Regulatory Precedents for Using NAMs for Decisions on Inhaled Substances: How to Promote Alternative Methods Without Eroding Public Health Protections?},
journal = {Toxicological Sciences},
year = {2026},
doi = {10.1093/toxsci/kfag152}
}
EUVIMED